Table 1 Patient characteristics
From: Induction maintenance concept for HAART as initial treatment in HIV infected infants
Patient | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
Mode of delivery | Caesarean (38th week) | Caesarean (29th week) | Caesarean | Caesarean (41st week) |
Prepartal prophylaxis | ZDV, 3TC, NVP (5 weeks) | None | None | None |
Intrapartal prophylaxis | ZDV | None | None | None |
Postnatal prophylaxis | ZDV (4 weeks) | 2 × NVP; ZDV + 3TC(6 weeks) | None | None |
Age at diagnosis | 4 weeks | 5 months | 2.5 months | 4.5 months |
Initial HIV-1 RNA load (copies/ml) | 500 000 | 16 000 | 139 670 | 3 600 000 |
Initial CD4 cell count (absolute cells, μl/%) | 3732/44 | 2515/43 | 1093/17 | 330/6 |
Initial CD4 cell count (ARP, %) | 106 | 100 | 44 | 13 |
4 drug HAART | ABC, 3TC, LPV, NVP | ABC, 3TC, LPV, NVP | ZDV, 3TC, NFV, NVP | ZDV, 3TC, LPV, NVP |
Maximal decline of viral load (log change and duration) | 5 log; 4.5 months | 4 log; 2 months | 5 log; 2 months | 5 log; 6 months |
Duration of 4 drug HAART | 11 months | 13 months | 13 months | 10 months |
Clinical toxicity | *Atopic dermatitis | None | None | None |
Laboratory toxicity | AST (1.4 × ULN - Grade 1); AP (2.2 × ULN -Grade 1); Cholesterol (235 mg/dl - Grade 2); *GGT (18.6 × ULN) | AP (1,4 × ULN - Grade 1); ▴CK (4.2 × ULN - Grade 1); *GGT (2.1 × ULN) | AP (1,2 × ULN - Grade); CK (2.2 × ULN - Grade 0), *GGT (7.2 × ULN) | AP (1.8 × ULN - Grade 1); CK (2.4 × ULN - Grade 0); *GGT(27 × ULN); Triglycerides (498 mg/dl - Grade 1) |
3 drug HAART | ABC, 3TC, NVP | ABC, 3TC, NVP | ZDV, 3TC, NVP | ZDV, 3TC, NVP |
Viral load at last visit (copies/ml) | 16801 | < 1 | < 1 | 48 |
Follow up time | 50 months | 50 months | 34 months | 27,5 months |